Viewray (VRAY) Received its Third Buy in a Row

After BTIG and Cantor Fitzgerald gave Viewray (NASDAQ: VRAY) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Viewray today. The company’s shares closed yesterday at $8.75.

Yang wrote:

“We also adjusted our 2019 revenue and new order forecast downward. We believe management is making the right investments and we expect the efforts to pay-off over time with 2-3 quarters of lag (more below). We updated our model and reduce our PT from $13 to $12. Reiterate Buy.”

According to, Yang is a 5-star analyst with an average return of 19.7% and a 48.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.

Viewray has an analyst consensus of Strong Buy, with a price target consensus of $15.06, a 72.1% upside from current levels. In a report issued on October 29, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $13.21 and a one-year low of $6.05. Currently, Viewray has an average volume of 1.51M.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.